GRTS
Gritstone Oncology Inc
NASDAQ: GRTS · HEALTHCARE · BIOTECHNOLOGY
$0.03
+0.00% today
Updated 2026-06-03
Market cap
$3.80M
P/E ratio
—
P/S ratio
0.26x
EPS (TTM)
$-1.09
Dividend yield
—
52W range
$0 – $0
Volume
—
Gritstone Oncology Inc (GRTS) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+14.5%
Last 4 quarters
Revenue YoY growth
-85.8%
Most recent quarter
EPS YoY growth
+48.4%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2024-06-30 | $-0.28 | $-0.16 | +42.9% | $57000.00 | -85.8% |
| 2024-03-31 | $-0.32 | $-0.34 | -6.3% | $49000.00 | -91.0% |
| 2023-12-31 | $-0.33 | $-0.26 | +21.2% | $29000.00 | -97.8% |
| 2023-09-30 | $-0.33 | $-0.33 | +0.0% | $1.56M | +258.9% |
| 2023-06-30 | $-0.35 | $-0.31 | +11.4% | $400000.00 | -85.5% |
| 2023-03-31 | $-0.33 | $-0.30 | +9.1% | $542000.00 | -88.6% |
| 2022-12-31 | $-0.34 | $-0.30 | +11.8% | $1.33M | -25.4% |
| 2022-09-30 | $-0.40 | $-0.35 | +12.5% | $436000.00 | -81.8% |
| 2022-06-30 | $-0.40 | $-0.34 | +15.0% | $2.76M | — |
| 2022-03-31 | $-0.37 | $-0.34 | +8.1% | $4.75M | — |
| 2021-12-31 | $-0.38 | $-0.37 | +2.6% | $1.78M | — |
| 2021-09-30 | $-0.52 | $-0.36 | +30.8% | $2.40M | — |
Frequently asked questions
Has Gritstone Oncology Inc beaten earnings estimates?
Gritstone Oncology Inc has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, averaging a +14.5% surprise over the last 4. A consistent beat record suggests management guides conservatively and the business has predictable momentum, which tends to support the stock through earnings season.
What is Gritstone Oncology Inc's revenue growth rate?
Gritstone Oncology Inc reported year-over-year revenue growth of -85.8% in its most recent quarter, with EPS up +48.4%. EPS outpacing revenue is operating leverage at work, meaning profit is compounding faster than sales.